PathAI Announces EMA Qualification for AIM-MASH AI Assist, a Groundbreaking AI Tool for MASH Clinical Trials
PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...
EU Medicines Agency assesses first AI diagnosis as "scientifically valid"
For the first time, the European Medicines Agency has recognized AI software for the diagnosis of fatty liver hepatitis as ...
Pharmabiz1d
EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples
EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...
Morningstar3d
PathAI Announces EMA Qualification for AIM-MASH AI Assist, a Groundbreaking AI Tool for MASH Clinical Trials
The EMA CHMP has determined that the proposed Artificial Intelligence-Based Measurement of Non-alcoholic Steatohepatitis Histology (AIM-MASH) tool can be used in metabolic dysfunction associated ...
Gyre: Intriguing Upcoming Data Catalyst, But I'm Still On Sidelines
Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...